Invivyd, Inc. announced new in vitro data demonstrating that its investigational monoclonal antibody PEMGARDA™ (pemivibart) continues to show consistent neutralizing activity against the dominant SARS ...
A state-of-the-art engineering approach toward improving the neutralizing activity of a cross-reactive nanobody, previously generated against the original SARS virus, showed it can be an attractive ...
WALTHAM, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today provided ...
In a recent study published in Science Immunology, researchers investigated the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) Omicron's immune escape mechanisms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results